FDA cited Somerset Therapeutics' India plant for CGMP failures tied to a contaminated media fill and aseptic processing risks.
What happened
FDA inspected the Somerset Therapeutics drug manufacturing facility in Karnataka, India, from February 10 to 21, 2025. FDA found inadequate investigations of a September 2024 media fill with visible contamination, out-of-specification impurity results, and aborted air-sampler events. During the inspection, FDA also observed tape securing a component to the interior ceiling of an ISO 5 filling area; the tape detached during aseptic manufacture of an injection, and FDA found aseptic interventions, material transfers, and airflow studies deficient.
What FDA found
Somerset did not thoroughly investigate unexplained batch failures or discrepancies, including a September 2024 media fill contamination, out-of-specification impurity results, and aborted air-sampler events.
21 CFR 211.192Somerset did not maintain equipment used to control aseptic conditions; FDA observed tape securing a component to the interior ceiling of an ISO 5 area, and the tape detached during aseptic manufacture.
21 CFR 211.42(c)(10)(vi)Somerset did not establish and follow adequate written procedures to prevent microbiological contamination and validate aseptic and sterilization processes, with deficiencies in interventions, material transfers, and airflow studies.
21 CFR 211.113(b)Somerset did not submit a Field Alert Report within three working days after identifying cloudy vials in a September 2024 media fill; it submitted one only after the inspection.
21 CFR 314.81(b)(1)(ii); section 505(k) of the FD&C Act
What FDA wants
FDA asks Somerset to correct the violations promptly and respond in writing within 15 working days with what it has done and how it will prevent recurrence; if corrective actions cannot be completed, it must give reasons and a schedule.
Who should pay attention
- companies that rely on Somerset as a contract manufacturer
- brands selling sterile injectables made at this site
- quality teams responsible for supplier oversight and Field Alert reporting
This is a summary. Read the original letter on fda.gov.